The current effectiveness of HAART in the management of HIV infection is compromised by
the emergence of extensively cross-resistant strains of HIV-1, requiring a significant need for …

Resistance to antiretroviral agents, and in particular the increasing levels of transmitted
resistant virus could offset the substantial gains won with potent antiretroviral therapy …

Background. The prevalence of drug resistance among persons with newly acquired human
immunodeficiency virus (HIV) infection is well documented. However, it is unclear to what …

In most European countries, HIV drug resistance testing has become a routine clinical tool.
However, its practical implementation in a clinical context is demanding. The European HIV …

Background: Primary HIV drug resistance has been associated with poor treatment outcome
of first-line highly active antiretroviral therapy (HAART) in several trials. The aim of the study …

The HIV-1 epidemic in Shanghai is rapidly increasing. To better understand the HIV-1
genetic diversity and the mutations associated with resistance to protease inhibitors (PIs) …

Since 1989, the emergence of resistant human immunodeficiency virus mutants has been
documented for any new antiretroviral agent introduced in the clinical setting; it is a major …

One concern with current antiretroviral therapy for infection with HIV is that certain
anatomical sites in the body are considered 'sanctuary sites'. What is commonly meant is …

Background: The substantial frequency of drug resistance in persons recently infected with
HIV implies exposure among HIV-uninfected individuals to HIV-infected persons with drug …

The prevalence of HIV-1 drug resistance mutations in naïve patients has been previously
shown to differ greatly with the geographic origin. The purpose of this study was to …